



Making Governance Work ... while the Goalposts Keep Moving..

Hjördís Árnadóttir, Director, Corporate Communications
07 NOV 2013



Forward Looking Statements

Statements contained in this presentation that refer to Actavis' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. For instance, any statements in this presentation concerning prospects related to Actavis' strategic initiatives, product introductions and anticipated financial performance are forward-looking statements. It is important to note that Actavis' goals and expectations are not predictions of actual performance. Actavis' performance, at times, will differ from its goals and expectations. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions; market acceptance of and continued demand for Actavis' products; the impact of competitive products and pricing; costs and efforts to defend or enforce intellectual property rights; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with governmental regulations applicable to Actavis' facilities, products and/or businesses; changes in the laws and regulations affecting, among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis' Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and Actavis' Annual Report on form 10-K for the year ended December 31, 2012. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements.

Bullets sent to J Boye

I'll be talking about the way we are consuming content is changing and how we at Actavis are reacting to meet those needs.

How we know we are not there yet, but still think we have a pretty solid foundation that we are building on. And that we'll get there.

How a 'hub-and-spoke' model with a team of good people is the key to speaking with one voice in 60 countries, even during times of change upon change, that's not likely to end anytime soon

How training and encouragement helps build a strong global team

How the people are backed up by tools, that work as a 'carrot', but if they don't we sometimes need to follow up 'with a stick'

How important it is to have centralized domain registration/management and c-suite support.

Our Changing Habits



Get the App

Magazines

Web Tools

Community

Support


More

Tech & Science


Travel




Let us Access your Content!



Where we are



Actavis Launches Generic Viagra® in Europe as Patents Expire
[http://www.actavis.com/en/medis/...](http://www.actavis.com/en/medis/)
 Sildenafil Actavis, the generic equivalent of Pfizer's Viagra®, is prescribed to the erectile dysfunction. Actavis' product was launched immediately after the patent expired in Austria, Denmark, France, Germany, Ireland, Italy, The Netherlands, Sweden, Switzerland and the United Kingdom.



India
 About Actavis > Global Locations > Commercial > Asia Pacific > India

Select Country
 Select

Actavis' presence in India dates back to 2001, when the Group established a sourcing office in the country. Today, Actavis employs more than 620 people in India, who between them deliver a fully integrated and highly cost-effective service.

Possibly the first generic pharmaceutical company from outside India to have a fully integrated operation in the country, Actavis now possesses a full range of services ranging from bio-equivalence studies to stability testing, developing and producing active pharmaceutical ingredients (APIs)—which are the single largest cost component of the business—developing new formulations and producing finished tablet forms.

Actavis Pharma Development
 Actavis Pharma Development heads the Group's strategic plans in India, sourcing active pharmaceutical ingredients (APIs) and finished dosage forms.

The Company is also exploring opportunities for formulation development, clinical trials, contract research and manufacture and new investment prospects in the country.

A strategic collaboration with Emcure Pharmaceuticals and subsequent agreements with other Indian pharmaceutical companies is ensuring a lower cost base for Actavis products in EU and US markets.

Lotus Laboratories
 In 2006 Actavis acquired Lotus Laboratories, an Indian Contract Research Organisation. Headquartered in Bangalore, Lotus was established in 2001 and employs over 230 people. The company specialises in the management of clinical trials to study the bio-availability and bio-equivalence of drugs, drug-drug interaction and early and late phase clinical trials. Existing

Actavis - Iceland

Actavis' subsidiaries in Iceland comprise its third-party sales division, Medis, and the manufacturing operations of Actavis hf. The Company has been in operation in Iceland continuously since 1956.

Medis


Medis, a combination of Medis and Specifar, provides a broad portfolio of products and intellectual property to other pharmaceutical companies. The Company specializes in generic pharmaceutical products for human use, mainly in the form of tablets, capsules and injections and a growing range of specialist oncology products. Additionally, Medis provides product development, licensing, product registration, intellectual property and supply chain services. The Company draws on the global resources and development and manufacturing capabilities of its parent company, Actavis.

Contact information:

Actavis Group hf.
 Dalshrauni 1
 220 Hafnarfirdi
 Iceland

Tel: +354 535 2300
 Fax: +354 535 2301

Actavis hf.
 Reykjavíkurveg 76-78
 220 Hafnarfirdi
 Iceland



Iceland
 About Actavis > Global Locations > Commercial > Europe > Iceland

Select Country
 Select

Actavis - Iceland

Actavis' subsidiaries in Iceland comprise its third-party sales division, Medis, and the manufacturing operations of Actavis hf. The Company has been in operation in Iceland continuously since 1956.

Medis

Medis, a combination of Medis and Specifar, provides a broad portfolio of products and intellectual property to other pharmaceutical companies. The Company specializes in generic pharmaceutical products for human use, mainly in the form of tablets, capsules and injections and a growing range of specialist oncology products. Additionally, Medis provides product development, licensing, product registration, intellectual property and supply chain services. The Company draws on the global resources and development and manufacturing capabilities of its parent company, Actavis.

Contact information:

Actavis Group hf.
 Dalshrauni 1
 220 Hafnarfirdi
 Iceland

Tel: +354 535 2300
 Fax: +354 535 2301

Actavis hf.
 Reykjavíkurveg 76-78
 220 Hafnarfirdi
 Iceland

Tel: +354 550 3300
 Fax: + 354 550 3001

Managing Director: Jon Gunnar Jonsson
 E-mail: jjonsson@actavis.is





It's a Different World

A Year Ago: Watson + Actavis

Watson Pharmaceuticals **actavis**

A Powerful Global Combination

more info

Featured Product
Rapaflo® (sildenafil) capsules

Recent News
10/12/2012 - Watson's Gener...
10/12/2012 - Watson's Gener...
10/5/2012 - Watson Receives Pending Actavis Acquisition...
10/1/2012 - Watson Confirms...

actavis think smart medicine

ACTAVIS БЪЛГАРИЯ

ACTAVIS БЪЛГАРИЯ

ACTAVIS БЪЛГАРИЯ ПРОДУКТИ НОВИНИ КАРИЕРИ ТЪРГОВСКИ КОНТАКТИ ACTAVIS ГРУП

Watson Pharmaceuticals **actavis**

A Powerful Global Combination

more info

ЛЕКАРСТВЕНИ ПРОДУКТИ НА ВЪЛНАТА НА ЗДРАВЕТО АКТУАЛЕН ПРОДУКТ ТЪРГ

Научи повече!

actavis think smart medicine

ABOUT ACTAVIS PRODUCTS SUPPLIES MEDIA CENTRE RESPONSIBILITY CAREERS CORPORATE DIRECTORY

Watson Pharmaceuticals **actavis**

A Powerful Global Combination

NEWS RESPONSIBILITY ACTAVIS WORLDWIDE

17 SEP 2012 / Other
Works on a new EUR13M warehousing project underway at Actavis in Malta

Over the coming months Actavis Ltd in Malta will be investing a total of EUR13M for the construction of a new warehouse adjacent to the plant. This investment is being made with the support of

25 JUN 2012 / Product
Actavis Receives Approval of Generic Adderall XR® CII in the US

Actavis is committed to protecting the environment and promoting the health & welfare of employees and the communities we operate in.

20 JUN 2012 / Comment
Actavis named Best Large Generic Manufacturer by US distributors

More about EHS Management

North America Europe Asia-Pacific

Privacy policy Sitemap Site terms

actavis think smart medicine

ACTAVIS JAPAN COUNTRY WEBSITES

ACTAVIS について 製品 メディアセンター 患者さん向け情報 キャリア 社会的責任

Watson Pharmaceuticals **actavis**

A Powerful Global Combination

ニュース アクタビスグループ ACTAVIS株式会社

2012/07/11 / Undefined
Actavisは、米国で活動している主要な流通業者より、最も優れたジェネリック医薬品企業であるとの評価を得ました。

Actavis U.S.は、世界的なジェネリック医薬品企業であるActavisグループの米国における調剤専攻企業です。同社はこの年（6月10日）、米国ヘルシウス薬業評価年（HONORARY）の「2012年ジェネリック医薬品リーダーシップ賞」で、ヘルシウス薬業の流通業者における重要な指標に評する2つの賞（D I A N A賞）を受賞しました。

2012/05/23 / その他
ワトソンのPaul Bisaro, CEOがスイス（ツーク）を訪問

アクタビスグループは、シエネリツク医薬品にフォーカスしたグローバルプレーヤーです。

Actavis株式会社は、2011年9月に、アクタビスグループ100%出資の日本法人として設立されました。

2012/04/25 / その他
アクタビスの買収に関するThor Björgólfssonの声明

2012/04/25 / その他
ワトソンがアクタビスを42億5000万ユーロで買収


Actavis株式会社について詳しくはこちら
Actavis株式会社について詳しくはこちら



January 24, 2012 - Watson became Actavis NYSE:ACT




Building to Specialty Pharmaceutical Leadership 2009 – Present




* Proforma Revenue


Actavis – A Specialty Pharmaceutical Company



The Way we Were – Legacy Actavis FY 2011



The Way we Are – New Actavis OCT 2013





It's Team Work

Rebranding the Company



The Corporate Site

The screenshot shows the Actavis corporate website homepage. At the top left is the Actavis logo, consisting of a stylized 'W' above the word 'Actavis'. To the right of the logo is a 'COUNTRY WEBSITES' link with a globe icon and a search bar. Below the logo is a green navigation bar with links for 'About Actavis', 'Global Business', 'Products', 'Investors', 'Responsibility', 'Media', 'Careers', and 'Contact Us'. The main content area features several sections: a large banner for 'Watson and Actavis are now Actavis' with a 'learn more' link; a 'RECENT NEWS' section listing three news items from May 2013; a video player for 'Act One' showing two scientists in a lab; a 'Product Database' section with an image of white pills; a 'Commitment to Quality' section with a blue background; and a 'NYSE' section showing the stock price 'ACT: 107.20' as of 4:00 PM ET on May 6. At the bottom is a green footer with copyright information and links for 'Legal/Copyright Disclaimer', 'Privacy Policy', 'Sitemap', 'Compliance', and 'Business Development'. A stock quote feed is also mentioned.

Actavis

COUNTRY WEBSITES

About Actavis | Global Business | Products | Investors | Responsibility | Media | Careers | Contact Us

Watson and Actavis are now Actavis [learn more](#)

RECENT NEWS

- 07/05/2013 Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health...
- 03/05/2013 Actavis to Host Annual Meeting of Stockholders on May 10, 2013
- 02/05/2013 Actavis First Quarter 2013 Net Revenue Increases 24% to \$1.9 Billion

We are the New Actavis

Act One

Product Database

Commitment to Quality

NYSE
ACT: 107.20
4:00 PM ET - May , 6

Copyright 2013 Actavis. All rights reserved. [Legal/Copyright Disclaimer](#) | [Privacy Policy](#) | [Sitemap](#) | [Compliance](#) | [Business Development](#)
Stock quote feed is powered by EDGAR Online. Intraday data is at least 20-minutes delayed. All times are EDT.

The Nordics



- Om Actavis
- Produkter
- Nyheder
- Job i Actavis
- Apotek
- CSR



En hurtig voksende virksomhed
Actavis er en af verdens førende virksomheder inden for udvikling, produktion og salg af farmaceutiske, generiske farmaceutiske produkter. Firmaet har gennemført mere end 20 opkøb i de seneste år og har samtidig haft en stærk organisk vækst. Senest har Vikalon Pharmaceuticals - Actavis Group mere end 17.000 ansatte i over 40 lande rundt om i verden.



DENMARK



- Om Actavis
- Produkter
- Nyheter
- Jobb i Actavis



En global leder
Actavis er det tredje største generiske legemiddelfølskabet i verden, med mer enn 750 molekyler i 1700 doseringskombinasjoner, som markedsføres globalt gjennom virksomheten i over 60 land. Actavis utvikler og markedsfører bioteknologiske produkter innenfor kreftbehandling, onkologi og andre terapeutiske områder. Actavis har produksjon, forskning og utvikling og kommersielle drift i mer enn 60 land, med tilgang til mer enn fem milliarder av verdens forbrukere.



NORWAY



ACTAVIS FINLAND



- Tietoa meistä
- Uutiset
- Tuotteet
- Työskentele meillä
- Korvapankki



Actavis, Inc. (NYSE:ACT) on kansainvälinen erikoistunut lääkealan yritys, joka kehittää, valmistaa ja myy useita rinnakkaislääkkeitä sekä lääkevalmisteita. Yhtiön pääkonttori sijaitsee Yhdysvalloissa, Mississippin osavaltiossa.



- Um Actavis
- Vörur
- Fréttir
- Mannauður
- Samfélag
- Fræðslufni



Hagur í heilsu



ISLAND

ACTAVIS SUOMI

Lääkään ja monipuoliseen tuotevalikoimaan kuuluu rinnakkaisvalmisteluiden lisäksi alkuperäislääkkeitä, itseohjautuvia lääkkeitä sekä oirelääkkeitä valmistusta.

Toimitusten sijainti
=> Henkilökunta

UUSIA TUC

Fluorid Free 1890kaj U-rift marklar Pagaractar Oraaldissus 1090kaj Act ja kasumee kásiikaupp: uutisi!



Official Sponsor

STORF-Í BOGI



Actavis er þriðja stærsta samheitaflaeyfingefélagi í heimi. Veltan á ársnu 2011 nátt tæpum 300 milljónum kílóna og heildarvæðist starfsmanna var rúmlega 10 þúsund í 40 löndum.

Starfsemi á Íslandi

LACTOCARE DAILY



Lactocare daily inniheldur mjólkurþyrpingafrætt sem eru laðir bóla uppöflou, fæðis og halda þarmflórannu í jafnvægi. Lactocare er fæðubótarefni og fæðit í spötkolum.

=> Nánar um Lactocare

ALLIR Á VÖLLINN



Actavis, sem er styttrarabill FH, býði í landtágrmu og handbóla, þefur, sumar, vor og haust. => Vinningshafar => Skráðu þig hér

=> Nánar um Lactocare

ÍBÜFEN - NYÞANNING



Þú er hægð að fá 50 stk af íbúfen 400 mg í glasi í laussölu. Íbúfen inniheldur íbúfenþrenn sem er bólgueyðandi, venjastjálendi og hlífðeigandi hf.

=> Nánar um Íbúfen



- QUICK LINKS
- SEARCH

ACTAVIS SMEDEN COUNTRY WEBSITES

- Om Actavis
- Produkter
- Actavis Online
- Arbeta hos oss
- Nyheter
- Kontakta oss



We are the New Actavis

NYHETER

02 MAJ 2013 / Produkt
Nyhet i White för vitare tänder
Den 6 maj lanserar Actavis en ny produkt - iWhite Produkten iWhite Instant säljs på apoteken från 6 maj. iWhite kan ge upp till 8 nyanser vitare tänder. I Apotekbladet 2 maj kan du läsa mer om
29 APR 2013 / Vårt ägande
Student sökes till vårt team Nordic Pharmaceutical Affairs

LANSERINGAR

Nu lanseras iWhite Instant - ett professionellt kit för snabbt vitare tänder. Produkten är utan väteperoxid. Kliniska studier har bevisat att iWhite Instant är 100% säker och ger dig snabbt vitare tänder, redan efter första appliceringen. Upp till 8 nyanser vitare tänder.
=> läs mer

ACTAVIS ONLINE

Actavis Online, portalen för dig som apotekspersonall Vi vill att alla som arbetar med våra produkter ska få tillgång till senaste nytt om våra produkter - snabbt, effektivt och direkt. Actavis Online är en portal utvecklad för dig som arbetar inom apoteksbranschen. Du kan även ta del av Actavisakademien med intressanta intervjuer och sjukfester inom läkemedelsområdet. Med Actavis Online får du detta och lite till. Registrera dig nu! www.actavisonline.se



ksforskning

lakemedelsföretag



BeNeLux



Actavis NETHERLANDS

Over Actavis | Producten | Nieuws en Informatie | Ondernemen | Carrière | Professionals

We are the New Actavis

NEWS

- 02 APR 2013 / Product
Easy Home Test Lyme - Tekenbeet
Teken zijn de boosdoeners als het gaat om de ziekte van Lyme. Deze insecten kunnen besmet zijn met de Borrelië bacterie die de ziekte van Lyme veroorzaakt. Jaarlijks worden 1 miljoen mensen...
- 02 APR 2013 / Product
Start herbeoordeling domperidon bevattende geneesmiddelen - CBG
- 01 MRT 2013 / Product
Nieuwe OTC zelfzorglijn: Easy Home Test

OVER ACTAVIS

Actavis ontwikkelt, produceert en verkoopt een breed pakket geneesmiddelen voor o.a. apotheken, ziekenhuizen en drogisten wereldwijd.

Kwaliteit en veiligheid staan daarbij voorop. Van productie onder de strengste EU-GMP-normen tot de verpakking en transport.

Graap werken wij samen met u aan optimale patiëntenzorg. Onze medewerkers staan voor u klaar met advies en service op maat.

NIEUW LOGO

Actavis blijft Actavis

Disclaimer | Site map | Site terms | Privacy policy

Actavis Inc. Baarsche Dijk 1 3741 LN Baarn • Tel 035 542 99 33 Fax 035 542 99 32 • info@actavis.nl @Actavis 2013



Actavis BELGIUM

Qui sommes nous? | Produits de réserve hospitaliers | News | Carrières

Portfeuille Actavis

Riche de plus de 30 molécules, le portefeuille hospitalier d'Actavis pour les produits d'oncologie est particulièrement fourni. Ces produits sont vendus dans le monde entier.

Les médicaments d'Actavis possèdent une qualité garantie et sont fabriqués conformément aux directives de BPF de l'UE.

NEWS

- 24 JANVIER 2013 / Autres
Watson Acquires Ubeon Pharma SA
- 14 JANVIER 2013 / Autres
Reprise du Groupe et du nom « Actavis »

Actavis reste Actavis

Actavis portfolio

Mit mehr als 30 Molekülen ist das Krankenhausportfolio von Actavis für Produkte für die Onkologie besonders gut bestückt. Diese Produkte werden weltweit verkauft.

Die Arzneimittel von Actavis bieten garantierte Qualität und werden nach den EU-GMP-Richtlinien hergestellt.

AKTUELLES

- 24 JAN 2013 / Autres
Watson Acquisés Ubeon Pharma SA
- 14 JAN 2013 / Autres
Name bleibt Actavis

WER SIND WIR?

Actavis Inc. ist ein weltweit führendes Pharmaunternehmen für die Entwicklung, Herstellung und den Vertrieb von generischen Markenprodukten und Biosimilars.

Actavis verfügt über Standorte für Produktion, Forschung und Entwicklung und Vertrieb in mehr als 60 Ländern, von wo aus weltweit mehr als 5 Milliarden Verbraucher erreicht werden können.

PRODUKTE

Flosover® berichtet die Produktpalette der Actavis Luxemburg. Flosover® ist erhältlich als Pulver zur Herstellung einer Injektionslösung und in Form von Kapseln.

Actavis bleibt Actavis

Site Map | Site terms | Disclaimer

Actavis Luxembourg, P/O box 61, 3500 Hasselt, Belgium • Tel 0032

Actavis BELGIUM

Qui sommes nous? | Produits de réserve hospitaliers | News | Carrières

Portfeuille Actavis

Riche de plus de 30 molécules, le portefeuille hospitalier d'Actavis pour les produits d'oncologie est particulièrement fourni. Ces produits sont vendus dans le monde entier.

Les médicaments d'Actavis possèdent une qualité garantie et sont fabriqués conformément aux directives de BPF de l'UE.

NEWS

- 24 JANVIER 2013 / Autres
Watson Acquisés Ubeon Pharma SA
- 14 JANVIER 2013 / Autres
Reprise du Groupe et du nom « Actavis »

Actavis reste Actavis

Actavis portfolio

Het ziekenhuisportfolio van Actavis Inc., voor oncologie producten is met meer dan 30 moleculen zeer omvangrijk. Deze producten worden wereldwijd verkocht. De geneesmiddelen van Actavis hebben een gegarandeerde kwaliteit en worden geproduceerd volgens EU-GMP-normen.

NIJWS

- 24 JAN 2013 / Overig
Watson Acquisés Ubeon Pharma SA
- 14 JAN 2013 / Overig
Naam blijft Actavis

WERKENS

Actavis Inc. is een wereldwijd, toonaangevend farmaceutisch bedrijf dat zich richt op de ontwikkeling, productie en distributie van generieke-merkproducten en biosimilars.

Actavis heeft productie-, R&D en Sales locaties in meer dan 60 landen, van waaruit wereldwijd meer dan 5 miljard consumenten bereikt kunnen worden.

DOCKETAXEL ACTAVIS 20 MCG/ML

Concentraat voor oplossing voor infusie, 1ml, 4ml, 7ml - Rascon.

Docketaxel is uitsluitend verkrijgbaar op medisch voorschrift.

Actavis blijft Actavis

Site Map | Site terms | Disclaimer

Hasselt, Belgium • Tel. 0000 99 662 • info@actavis.be @ Actavis 2013

UK, Ireland, Germany, Bulgaria, Serbia, Turkey, Brazil...

Actavis SERBIA COUNTRY WEBSITES

O nama | Proizvodi | Press | Pissao | Moj Actavis

We are the New Actavis

VESTI

07 MAJ 2013 / Porovodi
Bolesti srca ubije
Beograd, 7. maj 2013 -
da se Srbija ne nestane &
bolesti pojava je omogla

29 APR 2013 / Korporaci
Actavis ekspandira u
Leskovic

PROTEKTIN LINE

PROTEKTIN LINE - JER

Actavis

Sobre nós | Produtos | Notícias | Carreiras

We are the New Actavis

Erowlabs, subsidiária da Actavis, em Janeiro, Brasil. Estabelecida em 2008, possui aproximadamente 100 funcionários instalados no Rio de Janeiro.

NOTÍCIAS

13 MAR 2013 / Outros
Erowlabs revela identidade da Actavis, Inc. no Brasil

24 JAN 2013 / Outros
Erowlabs, uma empresa do Grupo Watson

Arquivos de notícias

FARMACOVIGILÂNCIA ACTAVIS

Veja aqui os que são eventos adversos e de segurança.

Leia mais

SERVIÇO DE CONSUMIDOR

Temos uma equipe de farmacêuticos para ajudá-lo (a) em suas dúvidas, sugestões e informações.

Actavis

About Actavis | Products | Media Centre | Careers | Responsibility

We are the New Actavis

A Global Leader in Generics

NEWS

10 MAY 2013 / Actavis News
New Actavis Academy App

Actavis is delighted to announce the launch of the Actavis Academy App on 1st May 2013. The App will allow existing and new users access to the complementary e-learning website direct.

18 APR 2013 / Actavis News
Arrow products join Actavis portfolio

27 FEB 2013 / Product News
Actavis announces their first day one Patent Expiry in 2013

MONTELIKAST LAUNCH

ACTAVIS ACADEMY APP

Actavis launch Montelukast Film-coated Tablets and Chewable Tablets

The new Actavis Academy App to assist learning on the go!

Access your Monthly Accumulator Price Lists Here

Privacy policy | Site terms | Sitemap

1151 Barnstaple Devon EX32 8NS • Switchboard +44 (0)1271 311 200 • Facsimile +44 (0)1271 346 106 • actavis@actavis.co.uk ©Actavis 2013

Actavis

Über uns | Karriere | Präparate | Aktuelles | Rabatfrage | Service

We are the New Actavis

NEWS

17 APR 2013 / Unidentified
Karlman Petro ist neuer Vice President Deutschland, Österreich, Schweiz und Bosnien

München, 16. April 2013 - Herr Karlman Petro hat mit der Position des Vice President neue Aufgabenbereiche für die Cluster DACH (Deutschland, Österreich, Schweiz) und Bosnien:

02 APR 2013 / Produkt
Starks Kräutchen mit Calcium D3 Actavis 1000 mg/800 I.E. Kautabletten

ACTAVIS DEUTSCHLAND

Actavis Inc. ist ein weltweit operierendes, integriertes Pharmaunternehmen, das sich der Entwicklung, Herstellung und dem Vertrieb von gentechnisch, Molekular- und Biologika-Produkten spezialisiert hat.

Präparate in Gruppen:

- Herzkreisläufige
- Neurologie
- Dermatologie
- Urologie
- Zahnbrechen
- OTC-Phyto
- Antibiotika
- Antidiabetika
- Lokalanästhetika
- Oncologie
- Bioprodukte

Die Fachabteilung Verbraucherschutz einzelner Präparate besteht werden.

Actavis

За нас | Продукти | Новини | Карриери | Търговски контакти | Actavis груп

We are the New Actavis

Ино сие Actavis - третата най-голяма международна генерична компания в света. Actavis България е най-голямата фармацевтична компания у нас с най-богата продуктова гама. Ние ви предлагаме качествени лекарства на достъпни цени.

Нашата мисия

Да разработваме и произвеждаме лекарствени продукти високо качество. Да посрещаме настоящите и бъдещите клиенти, като инвестирате умно в R&D.

ПОСЛЕДНИ НОВИНИ

10 АПРИЛ 2013 / Без категория
Actavis дарява медицината на България Червон кръж Команичана се отзовава на призива на проф. скарлатиност

14 МАРТ 2013 / Спонсор
Actavis е третата най-голяма генерична компания Мондиалър, стр.76,77 от 10 март 2013

» Архив новини

Actavis WORLDWIDE

ACTAVIS BULGARIA

Actavis TURKEY

Hakkımızda | Ürünlerimiz | Birimlerimiz | Ürünler | Kariyer | Otomatik | Bazen Olmaz | İletişim

Watson ve Actavis artık Actavis oldu

Çuvarın lideri eğer kaliteli ilaç, kaliteli arandı ve yarı Actavis, yüksek kaliteli ürünler geliştirdi, detay ve insan sağlığı sunar.

BASIN ODASI

01 KAS 2012 / Diğer
İLAÇ SEKTÖRÜNDE 5,50 MİLYAR DOLAR DEĞERİNDEKİ YÜKÜMLÜ BİRLEŞME TAAHHÜTLERİ

» Haber arşivi

ULUSLARARASI VARLIĞIMIZ

Actavis

About us | Products | News | Contact

We are the New Actavis

A Global Leader in Generics

For Actavis Products and Educational Materials please the Prescription Product

Actavis is pleased to announce the launch of the Actavis Academy App on 1st May 2013. The App will allow existing and new users access to the complementary e-learning website direct.

Just ask

Generic Medication awareness campaign

Sitemap | Privacy policy

Enniscorthy, Enniscorthy Park, Linn Island, Co. Wick, Ireland • Tel: +353 21461054 • info@actavis.ie © Actavis 2013

LEKARSTVENI PRODUKTI

НА ВЪПНАТА НА ЗДРАВЕТО

Здравето е важно условие да се радваме пълноценно на всички етапи от живота си, затова избираме сериата Actastayl за поддръжка на добрата форма при съвременния динамичен начин на живот.

» Actastayl

АКТУАЛЕН ПРОДУКТ

Ибудолор

Ибудолор облекчава болката и се използва при главоболие, зъбобол, ставни и мускулни болки, менструални болки и повишена температура.

» За Ибудолор

ЕВРОПЕЙСКИ

Договор за БФ Финансова по 11/28.12.2011 г. програмата "Ради конкурентност" на Българската и 2013

» Изпълнение

Actavis

Actavis, eğer ilaç, markalı ve ilaç-çözümler üreten bir şirkettir, en önemli ve en gelişmiş genetiklerin kullanıldığı ilaçları üretir. 2012 yılında Watson'la birleşerek Actavis adı altında faaliyetlerini sürdürmeye devam eden şirket, 750'den fazla moleküler olarak üretilen ilaçlarının dünya çapında dağıtım sistemleri ve dağıtım/retail alanındaki bütün önemli tedavi gruplarını kapsar.

ACTAVIS TÜRKİYE

Türkiye'de 2004 yılında faaliyetlerine başlayan Actavis, bugün 120 milyon tablet/doz ve 12 milyon küfürasyon üretilen kapsül/çözümler, 42 moleküler formatta, onkoloji, dermatoloji, metabolizma, kardiyovasküler, pediatri-üniter sistem, enfeksiyon, kas-iskelet sistemi, merkezi sinir sistemi, solunum sistemi ve gastroenteroloji alanındaki bütün önemli tedavi gruplarını kapsar.


ULUSLARARASI VARLIĞIMIZ

Site Haritası | Gizlilik Politikası | Kullanım Şartları

Ölçme Mah. Harman Cad. Ali Kaya Sokak Polat İş Merkezi No 3/B Blok kat:1-7-8 34384 Levent/İstanbul • Tel: (+90) 212 316 6700 • Faks: (+90) 212 264 4260 • info@actavis.com © Actavis 2013

Hub and Spoke

Adhitya Bakti Yoga **Alexandra** Sardareva
Ana-Maria Draganica **Aneta** Wieteska **Asdis**
Petursdottir **Barbara** Lovasova **Billy** Chung
Bryan B Van Steenberg **Catherine** Bissett
Cecilia Holmberg **David** Arias **David** Belian
Debbie McDonald **Djamshid** Ghavami **Elena**
Manzorro **Elisabet** Hjaltadottir **Ellen** Van
der Aart **Elma** Feng **Giedre** Bieliauskaite
Hildur Arnars **Hjordis** Arnadottir **Indre**
Vilimaite **Inga Lily** Gunnarsdottir **Ipek**
Uyunmas **Ivan** Kulic **Jiri** Mican **Karen**
Smaradottir **Lynda** Smyth **Maja**
Gedosev **Manuel** Barros **Marlene**
Hoj **Marnie** Peterson **Marcela** Sanches
Margret Barzacka **Martin** Pytlik **Mauro**
Abdilla **Milan** Cernek **Muriel** Neukom
Nyamsamba Dambiinyam **Olena** Vysotska
Ornella Caiazza **Pedro** Pêra **Radoslava**
Ganozova **Reny** Indrawati **Sabreena** Bhanji
Sandra Knebel **Sigfus** Orn Gudmundsson
Stephen Lem **Steve** Sost **Sunao** Katsuki
Susanne Lammer **Szilvia** Horvath **Wendy-**
Maria Gronloh **Yoyok** Indratmoko **Zoe** Hurst



Central Team?



Начало | За нас | Продукти | Новини | Кариери | Търговски контакти | Actavis груп

Дистрибутори

» Региони

РЕГИОНИ

Активис структурира пазара в страната на шест региона: Плевен, София, Пловдив, Благоевград, Варна и Бургас. Регионалните мениджъри отговарят за ефективното осъществяване на директни визити от страна на медицинските представители на Активис пред лекари, фармацевти, стоматолози и търговци на едро.

Основна цел на активностите е по-добро познаване на продуктите на Активис, както и по-ефективното им прилагане в съответните практики.

Активис е основен и лоялен партньор на лекарската, фармацевтичната и стоматологичната колегия, като компанията се стреми да ги подпомага в осигуряването на по-добър здравословен статус на българското население, чрез достъпно и качествено лечение и профилактика.



Пловдив

Танко Кашаров
Регионален мениджър
Тел: +359 88 5717447
tkasarov@actavis.bg

後発医薬品 (ジェネリック医薬品) の使用促進について

厚生労働省は、国民医療費の高騰を抑制するため、後発医薬品の使用促進を様々な形で推進しています。2013年4月には、「後発医薬品のさらなる使用促進のためのロードマップ」を示し、後発医薬品の促進を図る計画です。

このホームページでは、厚生労働省及びPMDAから発信されています情報を提供して行きます。

弊社では、これからも後発医薬品に関連する様々な情報を提供し、患者様が安心してご使用いただけますよう努力してまいります。

ジェネリック医薬品とは？

[ジェネリック医薬品とは？\(PDF, 1.32 MB\)](#)



STÖRF Í BODI

Actavis er séfellt í leit að hæfileikaríku fólki sem hefur áhuga á að starfa í ort vaxandi fyrirtæki með áhugasomu og metnaðarfullu starfsfólki.

Lýkibætur í starfsemi Actavis eru þjónustulund, samvinna, hagræðmi, sveigjanleiki, framsækni og metnaður. Allir sem hafa áhuga á að vera hluti af stærri höfundali Actavis eru hvattir til þess að sækja um.

Actavis er framsækil fyrirtæki, þar ríkir góður starfsandi og starfsöryggi er mikil. **Hér má sækja um:**

Auglýst störf í boði
Almenn starfsúmsókn

Undir auglýst störf í boði má finna frekari upplýsingar um laus störf í boði.

Meðhöndlu umsókn

Allar umsóknir eru meðhöndlaðar sem trúnaðarmál. Almennum umsóknum er ekki svarað sérstaklega en ef reynsla og hæfni umsækjenda nýtist mögulega í lausar stöður verður haft samband við viðkomandi.

Allar umsóknir eru geymdar í 9 mánuði, eftir þann tíma er þeim eytt. Ef ekki hefur komið til ráðningar innan þess tíma og enn er óskað eftir starfi, þarf að sækja um á ný. Ef umsækjandi kys að umsókn verði eytt innan þess tíma þá vinsamlega sendi tölvupóst á starf@actavis.is.

Mikilvægt að vanda til verka

Þar sem höfuð er útan um allar umsóknir í löbkerfi fyrirtækisins þurfa umsóknir að berast á því umsóknarform sem hér boðið er upp á. Vinsamlega athugið að hægt er að setja fenískra undir viðhengi.



Mikilvægt er að umsóknareyðublaðið sé fyllt út eins nákvæmlega og kostur er því leitað er eftir þeim upplýsingum sem umsækjendur skrá í kerfið varðandi menntun, hæfni o.s.frv. Með því að vanda til verka eykduðu möguleika þin á að fá starf.

AD SÆKJA UM STARF

» Auglýst störf í boði
» Almenn starfsúmsókn

Nánari upplýsingar vegna umsókna veitir starfsmannasvið.

1 8 隆



SEO Group score 8.5 <small>Community av. 6.0</small>	Accessibility Group score 9.5 <small>Community av. 6.6</small>	Usability Group score 9.5 <small>Community av. 6.5</small>	SEO ACC USE 	BENCHMARK <i>Compare with community averages</i>
---	---	---	------------------------	--

PROGRESS
Chart compliance change over time

ERRORS
Analyse error levels group-wide

KPIs
Track performance in key areas


What do these scores mean?

Website	SEO	Accessibility	Usability
Netherlands	10	10	10
Sweden	10	10	10
Germany	10	10	10
Switzerland FR	10	9.9	9.7
Denmark	10	10	10
Indonesia	10	10	10
Belgium NL	10	10	10
China	10	10	10
Baltics	10	10	10
Serbia	10	10	10
Belgium FR	10	10	10
Finland	9.9	10	10

+ 1,000 domains

- Actavis.at Actavis.ba Actavis.be
- Actavis.bg Actavis.ca Actavis.ch
- Actavis.cn Actavis.co.id Actavis.co.nz
- Actavis.co.uk Actavis.com
- Actavis.com.au Actavis.com.br
- Actavis.com.hk Actavis.com.mt
- Actavis.com.tr Actavis.com.ua Actavis.cz
- Actavis.de Actavis.dk Actavis.es
- Actavis.fi Actavis.fr Actavis.hu Actavis.ie
- Actavis.is Actavis.jp Actavis.lt Actavis.lu
- Actavis.mn Actavis.nl Actavis.no
- Actavis.pt Actavis.ro Actavis.rs Actavis.ru
- Actavis.se Actavis.si Actavis.sk ...

.com OCT 2013



Country sites
77-93% desktop

Actavis + Warner Chilcott At-a-Glance

- Acquired Warner Chilcott on October 1, 2013
- ~\$10 billion global pharmaceutical company
 - ~\$3 Billion specialty brand pharmaceutical company
- Doubles Actavis Specialty Brands portfolio
- Delivers industry-leading pipeline
 - 25+ products in various stage of development





Questions?
@Hjodda